Feasibility Study of Transarterial Chemotherapy Followed by Chemoembolization for Recurrent Breast Cancer.

PURPOSE: To assess the treatment response to transarterial chemotherapy followed by chemoembolization for locally recurrent breast cancer. MATERIALS AND METHODS: Thirty-nine women with locally recurrent breast cancer after standard therapy underwent selective intra-arterial chemotherapy followed by embolization using drug-eluting microspheres for locally recurrent tumors and axillary lymph node metastases. Tumor response and toxicity were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and Common Terminology Criteria for Adverse Events (CTCAE), and survival was evaluated by the Kaplan‒Meier method. RESULTS: The local responses of breast tumors at 3 and 6 months were as follows: complete response, 5.1% and 7.2%; partial response, 35.9% and 67.8%; stable disease, 59.0% and 21.4%; and progressive disease, 0.0% and 3.6%, respectively. All adverse events were mild and did not require treatment. The median overall survival (OS) was 46.5 months, and the OS rates for 1 and 2 years were 81.4% and 69.2%, respectively. The size of recurrent tumors and axillary lymph node metastases did not impact prognosis, but both liver and bone metastases adversely affected survival. CONCLUSION: Transarterial chemotherapy followed by chemoembolization may provide a favorable tumor response in patients with locally recurrent breast cancer in whom conventional therapy has failed.

Nanoemulsion-based silver ion-selective optode based on colorimetrically silver ion-responsive ionic liquid-based dye.

In this study, we describe the fast-responsive nanoemulsion (NE)-based silver ion (Ag+)-selective optode based on colorimetrically silver ion-responsive ionic liquid-based dye (ILD). The ILD comprises purely functional sensing molecules, a protonated cationic merocyanine dye (KD-M13-H+) and an anionic Ag+ ionophore (BDM-SO3-), and thus, it can be used for highly sensitive silver ion (Ag+) sensing due to the extremely high content of dye in the organic phase (ionic-liquid phase). However, during the Ag+ sensing, the cationic merocyanine dye is converted into electrically neutral form by deprotonation of the dye, which leads to the conversion of liquified dye into solid form in the organic phase, which makes the response time slower when ILD is used for poly(vinyl chloride) (PVC) membrane-based ion-selective optode, especially for sensing of high Ag+ concentration. To solve this problem, we focused on the use of the nano-emulsification technique. The response time of the ILD-based nanoemulsion (NE) was considerably shorter (1 s) compared to that of the ILD-based PVC membrane (a few minutes) owing to the large surface area and excellent diffusivity of the emulsion. The ILD-based NE contained a very high dye concentration (833 mmol kg-1) and exhibited approximately 12 times higher sensitivity than that of the plasticizer-based conventional NE. In the cation measurements, the ILD-based NE responded to Ag+ via a cation-exchange mechanism and demonstrated a highly selective response to Ag+ (log [Formula: see text] = - 3.0). ILD-NE was successfully applied to the detection of spiked Ag+ in a tap water sample with recoveries of 98 - 103% with a relative standard deviation (RSD) of less than 5%. In comparison with NE based on non-ionic ionophores without charge, NE based on BDM-SO3- responded to lower Ag+ concentrations owing to the effect of negative charge on the binding property. The novel ILD-based NE was capable of highly sensitive, rapid, and selective Ag+ sensing, providing potential for analytical devices applicable to high-performance on-site analysis.

Transarterial Treatment of Lung Cancer.

PURPOSE: The treatment efficacy of the transarterial approach to lung cancer is evaluated. MATERIALS AND METHODS: A total of 98 patients with advanced lung cancer or recurrent lung cancer after the standard therapies were enrolled retrospectively. The bronchial arteries and mediastinal branches from the subclavian artery were selected by a microcatheter. Immediately after the selective arterial infusion of anti-neoplastic agents, embolization with a spherical embolic material was carried out. Local tumor effects and overall survival were evaluated. RESULT: The mean reduction rate was 17.9%, with 24.2% for partial remission and with 2.1% for progression disease. The rate of stable disease was 72.6%. The response rate was 25.3%, and the disease control rate was 97.9%. The median survival time (MST) was 11.4 months, the 1-year survival rate was 45.2%, and the 2-year survival rate was 35.6%. Although it is insignificant, the MST for 51 adenocarcinomas was higher than that of 29 squamous cell carcinomas (18.6 months and 9.4 months, respectively). The local extension of tumors related to a better prognosis, though it was not significant. Lymph node metastases and distant metastases were poor prognostic factors. No major complications nor treatment-related mortalities were found in this study. CONCLUSION: The transarterial treatment for lung cancer should be considered as a treatment option when the other treatments were not indicated both in initial cases and in recurrent cases.